Exhibit 99.1 Co-Diagnostics Reports Full Year 2025 Financial Results Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI Integration and Expanding IP Portfolio Salt Lake City, UT – March 31, 2026 – Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the developmen ...